Structure of Infigratinib
CAS No.: 872511-34-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Infigratinib (BGJ-398; NVP-BGJ398) demonstrates potent inhibition against the FGFR family, displaying IC50 values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
Synonyms: NVP-BGJ398; BGJ398; BGJ-398
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 872511-34-7 |
| Formula : | C26H31Cl2N7O3 |
| M.W : | 560.48 |
| SMILES Code : | O=C(NC1=C(Cl)C(OC)=CC(OC)=C1Cl)N(C2=NC=NC(NC3=CC=C(N4CCN(CC)CC4)C=C3)=C2)C |
| Synonyms : |
NVP-BGJ398; BGJ398; BGJ-398
|
| MDL No. : | MFCD22123241 |
| InChI Key : | QADPYRIHXKWUSV-UHFFFAOYSA-N |
| Pubchem ID : | 53235510 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302 |
| Precautionary Statements: | P280-P305+P351+P338 |
| Target |
|
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| G401 cells | 100 nM | 5 min to 24 h | The phosphoproteome of G401 cells was measured in response to Infigratinib, showing significant downregulation of phosphorylation at FRS2 S428 and GAB1 T503, indicating inhibition of the FGFR signaling pathway by the drug. | Mol Syst Biol. 2024 Jan;20(1):28-55. |
| HCC01-0909 cells | 1 µM | 24 h | Inhibits FGF/FGFR signaling pathway and its downstream targets, leading to G1 cell cycle arrest | Hepatology. 2019 Mar;69(3):943-958. |
| ICC13-7 | 100 nM | 24 h | Evaluate the sensitivity of ICC13-7 cells to Infigratinib, showing an IC50 of 12 nM. | Cancer Discov. 2022 May 2;12(5):1378-1395. |
| ICC21 | 100 nM | 24 h | Evaluate the sensitivity of ICC21 cells to Infigratinib, showing an IC50 of ~250 nM. | Cancer Discov. 2022 May 2;12(5):1378-1395. |
| ICC10-6 | 100 nM | 24 h | Evaluate the sensitivity of ICC10-6 cells to Infigratinib, showing an IC50 >1000 nM, indicating resistance to Infigratinib. | Cancer Discov. 2022 May 2;12(5):1378-1395. |
| PDXO67 | 300 nM | 30 min | To confirm FGFR2c activation via endogenous FGF2 | NPJ Precis Oncol. 2023 Dec 8;7(1):127. |
| PDXO67 | 300 nM | 72 h | To evaluate the effect of BGJ398 on proliferation and cell death in PDXO67 | NPJ Precis Oncol. 2023 Dec 8;7(1):127. |
| MPM cell lines | 0.1 to 10 µM | 72 h | To evaluate the sensitivity of MPM cell lines to Infigratinib, 3 out of 13 cell lines were sensitive to Infigratinib, 4 were resistant, and the remaining 6 showed intermediate sensitivity. | Cells. 2019 Sep 16;8(9):1091. |
| ICC13-7 cells | 100 nM | 24 h | To investigate the effect of Infigratinib on glucose metabolism in ICC13-7 cells, the results showed that Infigratinib significantly suppressed glycolytic gene expression and reduced glucose uptake and lactate secretion. | Nat Commun. 2024 May 7;15(1):3805. |
| ICC21 cells | 100 nM | 24 h | To investigate the effect of Infigratinib on glucose metabolism in ICC21 cells, the results showed that Infigratinib significantly suppressed glycolytic gene expression and reduced glucose uptake and lactate secretion. | Nat Commun. 2024 May 7;15(1):3805. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| C.B-17 SCID mice | HCC PDX xenograft model | Oral | 10, 20, 30 mg/kg | Once daily for 14 days | Infigratinib significantly inhibits tumor growth, reduces tumor burden, and suppresses FGFR signaling pathway and its downstream targets | Hepatology. 2019 Mar;69(3):943-958. |
| Mice | ICC21 subcutaneous xenograft model | Oral | 15 mg/kg | Daily for 21 days | Evaluate the efficacy of Infigratinib combined with Afatinib in the ICC21 subcutaneous xenograft model, showing significant tumor regression with combination therapy. | Cancer Discov. 2022 May 2;12(5):1378-1395. |
| NSG mice | C666-1 xenograft model | Oral | 30 mg/kg | Once daily for 14 days | Evaluate the antitumor effect of Infigratinib on the C666-1 xenograft model, results showed that Infigratinib significantly inhibited tumor growth | Sci Adv. 2022 Apr 8;8(14):eabh2445 |
| Mice | NSG mice | Oral | 30 mg/kg | Once daily for 21 days | To evaluate the effect of Infigratinib on tumor growth inhibition and survival in EC PDX models | NPJ Precis Oncol. 2023 Dec 8;7(1):127. |
| Mice | ICC13-7 xenograft model | Oral | 15 mg/kg | Once daily for 10 days | To investigate the effect of Infigratinib on tumor growth in the ICC13-7 xenograft model, the results showed that Infigratinib significantly inhibited tumor growth and reduced glucose uptake. | Nat Commun. 2024 May 7;15(1):3805. |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT02706691 | FGFR Gene Amplification|FGFR1 ... More >>Gene Amplification|FGFR2 Gene Amplification|FGFR2 Gene Mutation|FGFR3 Gene Mutation|Head and Neck Squamous Cell Carcinoma|Human Papillomavirus Infection|Recurrent Head and Neck Carcinoma|Recurrent Nasopharynx Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma Less << | PHASE2 | TERMINATED | 2019-02-11 | University of Chicago Comprehe... More >>nsive Cancer Center, Chicago, Illinois, 60637, United States Less << |
| NCT04424966 | Glioma|Glioblastoma|GBM | EARLY_PHASE1 | TERMINATED | 2023-04-27 | Chandler Regional Medical Cent... More >>er, Chandler, Arizona, 85224, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, 85251, United States Less << |
| NCT02657486 | Bladder Cancer|Non-Muscle-Inva... More >>sive Urothelial Carcinoma Less << | ACTIVE_NOT_RECRUITING | 2025-01-26 | Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less << | |
| NCT03510455 | Tumor-Induced Osteomalacia|Onc... More >>ogenic Osteomalacia Less << | PHASE2 | TERMINATED | 2020-05-04 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
| NCT05019794 | Gastric Cancer|Gastroesophagea... More >>l Junction Adenocarcinoma|Solid Tumor Less << | PHASE2 | UNKNOWN | 2023-12-30 | Beijing Cancer Hospital ( Depa... More >>rtment of Thoracic Oncology ), Beijing, Beijing, 100142, China|Beijing Cancer Hospital (Department of Gynecological Oncology), Beijing, Beijing, 100142, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China|Affiliated Hospital of Hebei University, Baoding, Hebei, 071030, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Hubei Cancer Hospital, Wuan, Hubei, 430079, China|The First People's Hospital of Changzhou, Changzhou, Jiangsu, 213004, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, 210008, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, 200032, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, 030013, China|The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw hospital, Zhejiang University school of Medicine, Hangzhou, Zhejiang, 310016, China|Henan Cancer Hospital, Henan, Zhengzhou, 450008, China Less << |
| NCT05222165 | Advanced Solid Tumor|CNS Tumor... More >>|Recurrent WHO Grade II Glioma Less << | PHASE1|PHASE2 | WITHDRAWN | 2022-12-16 | Lucile Packard Children's Hosp... More >>ital at Stanford University Medical Center, Palo Alto, California, 94304, United States|Children's National Hospital - Brain Tumor Institute, Washington, District of Columbia, 20010-2916, United States|Nicklaus Children's Hospital, Miami, Florida, 33155, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Duke Cancer Institute (DCI) - The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, 27702-3624, United States|UPCM - Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15224-1529, United States|University of Alberta - Stollery Children's Hospital (SCH), Edmonton, Alberta, T6G 2B7, Canada|McMaster Children's Hospital (MCH), Hamilton, Ontario, L8N 3Z5, Canada|University of Toronto - The Hospital for Sick Children (SickKids), Toronto, Ontario, M5G 1X8, Canada|Universitaetsklinikum Heidelberg (UKHD) - Zentrum fuer Kinder- und Jugendmedizin - Klinik Kinderheilkunde III, Heidelberg, Baden-Wuerttemberg, 69120, Germany Less << |
| NCT01975701 | Recurrent Glioblastoma or Othe... More >>r Glioma Subtypes Less << | PHASE2 | COMPLETED | 2018-10-03 | Novartis Investigative Site, L... More >>os Angeles, California, 90095, United States|University of California San Francisco Dept of Onc., San Francisco, California, 94101, United States|Novartis Investigative Site, Chicago, Illinois, 60611, United States|Novartis Investigative Site, Boston, Massachusetts, 02215, United States|Novartis Investigative Site, New York, New York, 10032, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Dallas, Texas, 75246, United States|Novartis Investigative Site, Dallas, Texas, 75251, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, Melbourne, Victoria, 3050, Australia|Novartis Investigative Site, Leuven, 3000, Belgium|University Medical Center Utrecht, Utrecht, The Netherlands, 3508 GA, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28050, Spain|Novartis Investigative Site, Zürich, 8091, Switzerland Less << |
| NCT06206278 | Gastric Cancer|Gastroesophagea... More >>l Junction Adenocarcinoma Less << | PHASE2 | TERMINATED | 2024-05-31 | Anhui Provincial Cancer Hospit... More >>al, Hefei, Anhui, 230031, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China|Beijing Cancer Center, Beijing, Beijing, 100142, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|The Second Hospital Lanzhou University, Lanzhou, Gansu, 730030, China|Dongguan City People's Hospital, Dongguan, Guangdong, 523059, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, 510180, China|The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China|The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541199, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545006, China|Affiliated Hospital of Hebei University, Baoding, Hebei, 071030, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, 430030, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Hunan Provincial People's Hospital, Changsha, Hunan, 410002, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, 210008, China|Jilin Cancer Hospital, Changchun, Jilin, 130012, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110002, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250013, China|Shandong Provincial Cancer Hosptial, Jinan, Shandong, 250117, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266000, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, 200032, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, 030013, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|Sichuan Cancer Hospital, Chengdu, Sichuan, 610042, China|Tianjin Medical University Cancer Institute&Hospital, Tianjin, Tianjin, 300060, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China|The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310013, China Less << |
| NCT04972253 | Bladder Transitional Cell Carc... More >>inoma|Bladder Cancer|Fibroblast Growth Factor Receptor Less << | PHASE1 | WITHDRAWN | 2025-12-23 | - |
| NCT01697605 | Tumor With Alterations of the ... More >>FGF-R Less << | PHASE1 | COMPLETED | 2019-02-07 | Novartis Investigative Site, G... More >>uangzhou, Guangdong, 51000, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Guangzhou, 510060, China|Nagoya University Hospital, Nagoya-city, Aichi, 466-8560, Japan|National Cancer Center Hospital East (NCEE), Kashiwa, Chiba, 277-8577, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, 650-0017, Japan|Novartis Investigative Site, Sayama, Osaka, 589 8511, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, 411-8777, Japan Less << |
| NCT04233567 | Advanced Malignant Solid Neopl... More >>asm|Cholangiocarcinoma|Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-12-31 | Ohio State University Comprehe... More >>nsive Cancer Center, Columbus, Ohio, 43210, United States Less << |
| NCT01004224 | Advanced Solid Tumors With Alt... More >>erations of FGFR1, 2 and or 3|Squamous Lung Cancer With FGFR1 Amplification|Bladder Cancer With FGFR3 Mutation or Fusion|Advanced Solid Tumors With FGFR1 Amplication|Advanced Solid Tumors With FGFR2 Amplication|Advanced Solid Tumors With FGFR3 Mutation Less << | PHASE1 | COMPLETED | 2018-10-08 | Novartis Investigative Site, D... More >>uarte, California, 91010 3000, United States|Novartis Investigative Site, Los Angeles, California, 90033, United States|Novartis Investigative Site, Los Angeles, California, 90095, United States|University of Colorado Dept. of Anschutz Cancer (3), Aurora, Colorado, 80045, United States|Novartis Investigative Site, New Haven, Connecticut, 06520, United States|Novartis Investigative Site, Boston, Massachusetts, 02114, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Memorial Sloan Kettering Cancer Center Onc. Dept.., New York, New York, 10021, United States|Novartis Investigative Site, New York, New York, 10029, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University Hospital Onc Dept, Philadelphia, Pennsylvania, 19107-5098, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15232, United States|Novartis Investigative Site, Memphis, Tennessee, 38120, United States|Novartis Investigative Site, Nashville, Tennessee, 37203, United States|Novartis Investigative Site, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Vienna, A-1100, Austria|Novartis Investigative Site, Bordeaux Cedex, 33075, France|Novartis Investigative Site, Lyon Cedex, 69373, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Montpellier Cedex 5, 34298, France|Novartis Investigative Site, Paris, 75015, France|Novartis Investigative Site, Saint-Herblain Cédex, 44805, France|Novartis Investigative Site, Suresnes, 92150, France|Novartis Investigative Site, Toulouse Cedex 9, 31059, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, 50937, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Marburg, 35039, Germany|Novartis Investigative Site, Ramat Gan, 5265601, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Meldola, FC, 47014, Italy|Novartis Investigative Site, Seoul, Korea, 05505, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Singapore, 169610, Singapore|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46009, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28050, Spain|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Chiang Mai, 50200, Thailand|Novartis Investigative Site, Izmir, 35040, Turkey Less << |
| NCT02160041 | Solid Tumor|Hematologic Malign... More >>ancies Less << | PHASE2 | TERMINATED | 2018-04-30 | Alabama Oncology St. Vincent's... More >> Birmingham, Birmingham, Alabama, 35211, United States|North County Oncology Medical Clinic Inc, Oceanside, California, 92056, United States|San Francisco General Hospital San Francisco Gen Hosp (7), San Francisco, California, 94110, United States|Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50), Greenwood Village, Colorado, 80304, United States|Norwalk Hospital, Norwalk, Connecticut, 06856, United States|Florida Cancer Specialists Florida Cancer Specialists 36, Fort Myers, Florida, 33901, United States|University of Miami Sylvester Comprehensive Cancer, Miami, Florida, 33136, United States|NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta, Georgia, 30060, United States|Harbin Clinic Medical Oncology Clin. Res., Rome, Georgia, 30165, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, 60005, United States|Lurie Children's Hospital of Chicago Developmental Therapeutics, Chicago, Illinois, 60611, United States|Community Clinical Research Center, Anderson, Indiana, 46011, United States|Indiana University Indiana Univ. - Purdue Univ., Indianapolis, Indiana, 46202, United States|Northern Indiana Cancer Research Consortium No. Indiana Cancer Res., South Bend, Indiana, 46617, United States|University of Louisville / James Graham Brown Cancer Center SC, Louisville, Kentucky, 40202, United States|St. Agnes Hospital St. Agnes Hospital (2), Baltimore, Maryland, 21229, United States|Southcoast Centers for Cancer Care, Fairhaven, Massachusetts, 02719, United States|Cancer and Hematology Centers of West Michigan Dept. of Oncology, Grand Rapids, Michigan, 49546, United States|Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27), Minneapolis, Minnesota, 55404, United States|Research Medical Center Research Med Center (2), Kansas City, Missouri, 64132, United States|Billings Clinic Billings Clinic (8), Billings, Montana, 59101, United States|Dartmouth Hitchcock Medical Center Dartmouth Hitchcock - Lebanon, Bedford, New Hampshire, 03110, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|New Mexico Cancer Center, Albuquerque, New Mexico, 87109, United States|Waverly Hematology Oncology, Cary, North Carolina, 27518, United States|University of N C at Chapel Hill Physician Office Building, Chapel Hill, North Carolina, 27599-7600, United States|Duke University Medical Center Seeley G. Mudd Bldg., Durham, North Carolina, 27710, United States|Wake Forest Baptist Health Hem & Onc Medical Center, Winston-Salem, North Carolina, 27157, United States|Sanford Hematology Oncology, Fargo, North Dakota, 58122, United States|Oncology Hematology Care Inc Oncology Hematology Care 2, Cincinnati, Ohio, 45242, United States|University Hospitals of Cleveland Seidman Cancer Center University Hospitals, Cleveland, Ohio, 44106, United States|Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio, 44195, United States|Bend Memorial Clinic Bend Mem. Clinic, Bend, Oregon, 97701, United States|Northwest Cancer Specialists Northwest Cancer, Portland, Oregon, 97210, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, United States|Cancer Treatment Centers of America Eastern Regional Medical Center, Philadelphia, Pennsylvania, 19124, United States|University of Pittsburgh Cancer Institute Hillman Cancer Center (2), Pittsburgh, Pennsylvania, 15232, United States|Rhode Island Hospital Rhode Island Hosp. (2), Providence, Rhode Island, 02903, United States|Sanford University of South Dakota Medical Center Sanford Health, Sioux Falls, South Dakota, 57104, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology Tennessee Oncology (3), Nashville, Tennessee, 37203, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|Oncology Consultants Oncology Group, Houston, Texas, 77024, United States|Houston Methodist Cancer Center, Houston, Texas, 77030, United States|MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston, Texas, 77030, United States|Texas Oncology, McAllen, Texas, 78503, United States|Cancer Therapy & Research Center UT Health Science Center Oncology Dept., San Antonio, Texas, 78229, United States|Texas Oncology Cancer Care & Research Center Texas Oncology, Waco, Texas, 76712, United States|Deke Slayton Cancer Center Deke Slayton Cancer Center (2), Webster, Texas, 77598, United States|Intermountain Medical Center Intermountain Healthcare, Murray, Utah, 84157, United States|Northern Utah Cancer Associates Northern Utah Assoc (3), Ogden, Utah, 84403, United States|University of Utah / Huntsman Cancer Institute SC-2, Salt Lake City, Utah, 84103, United States|Utah Cancer Specialists Utah Cancer Specialists (11), Salt Lake City, Utah, 84106, United States|Virginia Cancer Specialists Fairfax Northern Virginia, Fairfax, Virginia, 22031, United States|Shenandoah Oncology Shenandoah Oncology (5), Winchester, Virginia, 22601, United States|Northwest Medical Specialties NW Medical Specialties, Tacoma, Washington, 98405, United States Less << |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.78mL 0.36mL 0.18mL |
8.92mL 1.78mL 0.89mL |
17.84mL 3.57mL 1.78mL |
|
Tags: Infigratinib | BGJ-398 | NVP-BGJ398 | BGJ398 | BGJ 398 | FGFR | Apoptosis | Fibroblast growth factor receptor | inhibit | MAPK | PI3K-Akt signaling pathways | angiogenesis | FGFR-driven cancer | cholangiocarcinoma | 872511-34-7
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


